Northwestern Medicine scientists have discovered two successful therapies that slowed the progression of pediatric leukemia in mice, the first step towards a pediatric leukemia “super drug.”
Inhibiting CHAF1B, a protein that normally helps replenish blood cells, may be a promising treatment for leukemia, according to a recent study.
From fundamental new understandings of the cell published in Nature to landmark clinical trials in the New England Journal of Medicine and cross-disciplinary collaborations in Science Translational Medicine, investigators throughout our institution have advanced new knowledge that is already transforming their diverse fields.
The Simpson Querrey Center for Epigenetics is connecting the Northwestern academic and medical community to integrate the study of epigenetics into science and clinical care.
Targeting cancer cells with a transcription elongation inhibitor delayed tumor progression in animal models, according to a recent Northwestern Medicine study.
The three-dimensional atomic structure of the epigenetic driver COMPASS was solved for the first time in a study published in the journal Cell.
Ali Shilatifard, PhD, has been appointed editor of Science Advances, an open-access journal published by the American Association for the Advancement of Science, which also publishes the journal Science.
Northwestern Medicine scientists have discovered an epigenetic imbalance that can lead to cancer, and used these findings to inhibit tumors in models.
Northwestern Medicine scientists have discovered a new compound that halts the spread of multiple types of cancer cells.
Northwestern Medicine scientists have uncovered new findings about a protein called SET1B, which could offer a novel approach to treating triple-negative breast cancer.